Objectives: To evaluate the diagnostic performance of 18 F-flurodeoxyglucose positron emission tomography/ computed tomography in patients with suspected biochemical ovarian tumor recurrence in comparison to contrast enhanced CT. Patients and Methods: A total of 64 18 F-FDG PET/CT studies for patients with biochemical suspicious ovarian tumor recurrence were evaluated. Each patient underwent 18 F-FDG PET/CT and Ce-CT scans in the same day. Studies were read independently by one experienced nuclear medicine physician and one experienced radiologist. A four-point score (score 0 = definitely benign, score 1 = probably benign, score 2 = probably malignant and score 3 = definitely malignant) used to assess the presence or absence of recurrence (local, regional or distant).
INTRODUCTION:
Ovarian cancer has a propensity for recurrence after treatment, even after surgery and adjuvant chemotherapy in early-stage tumors. Response rates to this standard primary treatment are approximately 80%, but survival rates are low. Approximately 20% to 30% of patients with early-stage disease and 50% to 75% of patients with advanced disease who obtain a complete response after first-line chemotherapy will ultimately develop a recurrent disease. Most patients with treated ovarian cancer relapse or die within 5 years of diagnosis.
(1) Therefore, a close followup is essential utilizing non-invasive technique such as tumor marker levels and imaging scans. (2) While the level of CA-125 has been shown to be a sensitive marker for tumor recurrence and levels may rise 3 to 6 months before there is clinically apparent disease, it does not provide information concerning the size and distribution of the lesions.
(1, 3, 4) Levels may also increase in a number of benign conditions, being a non-specific marker for ovarian cancer, and some patients, with relapse of disease, present with normal CA-125 levels. (3, 4) CT uses morphologic criteria to detect the disease and diagnose metastasis and abnormalities by evaluating the size of the lymph nodes. But sometimes normal-sized lymph nodes may be diseased, while enlarged nodes may be due to inflammation, hence may be free of disease. Moreover, accurate detection of intra-abdominal tumor recurrences may be limited due to difficulties in identifying small tumor deposits and in separating bowel structures from adjacent tumor tissue. Even if the tumor is detected, CT cannot confirm the lesion as tumor recurrence if it is too small. (5) Also metastases from ovarian cancer are unlike most other tumors in that they are primarily peritoneal rather than parenchymal in location. Therefore, they usually occur on the surfaces of the viscera rather than as masses within the viscera. These tumor implants can be miliary and isoattenuating relative to the viscera at computed tomography (CT), which makes their detection challenging. (6) FDG-PET/CT imaging for ovarian cancer surveillance has proven useful for detecting early recurrences with a diagnostic accuracy of approximately 80%. (7, 8) Recognized limitations include failure to detect small lesions with all three modalities and misinterpretation of normal physiological abdominal activity on PET. Integrated PET/CT offers the combined benefits of anatomical and functional imaging, and has been used to localize areas of increased FDG uptake with improved sensitivity and specificity. (9) (10) (11) . In this work, we sought to explore the possible role of PET/CT using 18 F-FDG compared to Ce-CT for detection of ovarian tumor residual/ recurrence when tumor markers are elevated.
PATIENTS AND METHODS:
Patients: This prospective study was conducted in Alfa Scan Radiology Center, during the period from January 2010 to November 2012. The inclusion criteria: patients with pathologically proven ovarian cancer who were treated with initial standard treatments, referred for post-treatment surveillance for detection of residual disease or recurrence. Patients referred for initial staging or with synchronous or past history of other cancers were excluded together with those who lost their follow-up. The study was approved by the Institutional Review Board, and each patient signed a written informed consent form.
PET/CT Imaging Protocol
The 18 F-FDG PET/CT scans were acquired using a Philips Gemini Timeof-Flight PET/CT machine equipped with LYSO crystals (Philips, Holland). The patients were instructed to fast for at least 6 hours before imaging and their blood glucose level was measured at the time of the tracer injection and was less than 160 mg/dl. A dose of 0.1-0.14 mCi/Kg was injected intravenously and adjusted according to patient's weight. For the optimal delineation of bowel structures, 400-600 ml of diluted mannitol solution was administered 1 hour before CT imaging. Approximately 60 minutes after tracer administration, a low-dose CT scan (5-mm contiguous axial cuts) was obtained in a 64 integrated multi-slice CT machine, from the skull base to the midthigh.
The acquisition was obtained in a helical mode, using 120 kV, 60mAs, and a 512 x 512 matrix size, acquiring a field of view (FOV) of 700 mm in 22.5 seconds. The first CT scan was used for attenuation correction. Immediately after the low-dose CT, an emission PET scan was acquired in a threedimensional mode over the same anatomical regions starting from the skull vertex to the level of the midthigh. The acquisition time was 2 minutes per bed position in 9 bed positions, with a one-slice overlap at the borders of the FOV. Finally, a diagnostic CT was acquired using 120 kV, 300 mAs, and a 512 x 512 matrix size. The acquired FOV was 500 mm using dose automatic modulation in the Z direction. The radiation exposure dose from low-dose CT was in average 3.37 milli Gray (mGy) while that for diagnostic CT was 11.48 mGy. After completion of acquisition, the images were reconstructed with a standard iterative algorithm, and then the reconstructed CT attenuationcorrected PET images, low dose CT images and Ce-CT images were transferred to the viewing stations for reviewing in axial, coronal, and sagittal planes and in a maximum-intensityprojection (MIP) three-dimensional cine mode using the manufacturer's review station (Brilliance, Philips, Holland). Semi-quantitative analysis of the 18F-FDG uptake in the suspected lesions was carried out by calculating the maximum standardized uptake values of each lesion using a rounded region of interest tool and a systematic slice by slice search for the most intense voxel within a given lesion.
Data Interpretation:
The fused PET/CT and Ce-CT images were separately interpreted by a team of one nuclear medicine physician and one radiologist with knowledge of aim of the study. For each study, 11 sub-sites were evaluated for the presence or absence of abnormality and recorded in a special database. A four-point score was used to describe the possibility of malignancy for each sub-site: score 0 = definitely benign, score 1 = probably benign, score 2 = probably malignant and score 3 = definitely malignant. The sub-sites were: local tumor site, peritoneum, pelvic LNs, abdominal LNs, mediastinal LNs, cervical LNs, liver, lung, bone, brain and other sites (pleura, muscles, adrenal glands).
Follow up:
The final diagnosis of the presence or absence of recurrent/ residual disease was made on the basis of subsequent follow-up by conventional imaging (CT/MRI), tumor markers, PET/CT and/or clinical follow-up of at least 6 months or histopathological findings obtained during surgery or biopsy whenever possible. Clinical recurrence was defined as the detection of recurrent disease by subsequent PET / CT, Ce-CT or a continuously rising CA-125 level to a value greater than twice the nadir within 6 months of the FDG PET/CT scan. Recurrent disease detected more than 6 months after the FDG PET/CT scan was interpreted as a new recurrence. 
RESULTS:
Patients: A total of 64 studies from 55 patients with ovarian cancer were eligible for this study. The general characteristics of the 55 patients enrolled in this study were summarized in (Table 1 ). The median age was 54 year (range: 13-76) with the majority of the patients having epithelial tumors (89.1%). Ce-CT and PET/CT were concordantly TN in 1/3 studies (Table 3) . PET/CT excluded disease in 2 FP studies by Ce-CT with no statistically significant difference in-between. Both modalities were TP in 52 studies (Table 3) . Additionally PET/CT diagnosed disease in 7/8 FN results by Ce-CT with marginal statistically difference (P 0.07).The difference of the overall accuracy as proved by ROC analyses (Fig.1 ) was statistically significant (P=0.02).PET/CT truly diagnosed recurrent disease in 7/9 studies with normal/ equivocal Ce-CT and excluded disease in 2/55 studies with abnormal Ce-CT (Fig.2) .
DISCUSSION:
The usefulness of concurrent FDG PET/CT for post-treatment surveillance of patients with ovarian cancer has been investigated in several studies. (12) (13) (14) (15) the overall reported sensitivity, specificity and accuracy of patient-based analyses were 73-100%, 40-100% and 63-100% respectively. In this work, 64 cases represented with elevated tumor markers; 9 with normal/equivocal Ce-CT and 55 with abnormal Ce-CT (Fig.  2) . According to the final status, 61/64 studies were positive for residual/ recurrence. The sensitivity, specificity and accuracy for PET/CT were 97%, 100% and 97% respectively compared to 87%, 33%, 84% respectively by Ce-CT. There was statistically significant difference in accuracy (P=0.02). Although PET/CT had higher sensitivity and specificity, there was marginal difference in sensitivity (P=0.07). Although the difference in percentage of specificity was high (100% for PET/CT and 33% for Ce-CT); however, this difference was obtained from a very small group of patients (n = 3) who were truly diseasefree on final follow-up. PET/CT showed no false positive results while Ce-CT mis-diagnosed 2 of them as having disease. It is assumed that patients with high tumor markers had a high pre-test probability of residual/recurrence disease, given that 95% of patients proved to have disease on follow-up with only 3 TN studies yielding 60% NPV; hence, negative PET/CT results should be taken cautiously. Among 9 studies with elevated tumor markers and normal/ equivocal Ce-CT, PET/CT was TP in 7 studies, FN in one study and TN in another study. PET/CT identified unsuspected disease in 7 studies (78%); 3 studies with normal sized lymph nodes and 4 studies with small peritoneal nodules missed by Ce-CT (16) (17) (18) (19) . This emphasizes the added value of PET/CT in this study. The only FN PET/CT study in this sub-group proved to have abdominal recurrence (peritoneal metastases) on second-look laparotomy (SLL) 3 months later ( Figure 3 ). This could be explained by the inherent limitation of resolution of PET/CT for detection of miliary peritoneal metastases < 5mm. Among 55 studies with elevated tumor markers and abnormal Ce-CT, PET/CT correctly confirmed residual/recurrence in 52 studies, excluded disease in 2 studies (2 TN) and missed residual/recurrence disease in one study (1 FN) . One TN patient referred 1 month after initial standard treatment (Surgery+ CTH) where Ce-CT showed 2.8 cm hepatic focal lesion and considered as positive for residual disease. The lesion remained stable over a period of 15 months upon second Ce-CT and PET/CT studies with normalization of CA-125 level, thus excluding the presence of residual disease. The second TN study in this subgroup was in a patient with perihepatic hypodense peritoneal nodule that was remained stable for 9 months upon second PET/CT imaging. Due to the narrow time interval between primary standard treatment and PET/CT, it was expected that morphological changes takes time more than metabolic changes explaining the inability of Ce-CT in differentiating between residual active disease and necrosis/fibrosis. (20) (21) (22) (23) The FN PET/CT study in this sub-group had a 7-mm pulmonary nodule in Ce-CT that was confirmed to be metastatic on follow-up and the patient received CTH with subsequent resolution of nodule and normalization of tumor marker level. Generally, the diagnostic performance indices of combined PET/CT come in line with those reported in literature. (24) (25) (26) (27) However, the sensitivity of Ce-CT is generally higher than others reported in literature. (24, 25, 28, 29) . In our work, Ce-CT was performed using a diagnosticlevel high-dose 64-slice machine for the whole body simultaneously with PET/CT and interpreted using volume images rather than reconstructed 3-5 mm slices. Most of the other studies were retrospective studies, CT was not performed on the same setting and contrast enhancement is not mentioned clearly in their methods. Also some authors correlated PET/CT with conventional imaging other than CT. This work suffers some limitations; firstly, lack of histopathologic correlation of all the sites of abnormal 18 FDG uptake. The confirmation of all the sites would not have been ethical solely for the purpose of validation of PET/CT findings. Secondly, impact of PET/CT on change of management and cost-effectiveness of PET/CT versus Ce-CT was not feasible in current study. Data collection about the planned treatment before and after Ce-CT could not be reached. Lastly, semiquantitative parameters as SUV and metabolic tumor volume that may have prognostic significant were beyond the scope of this study. Advantages of this study include prospective design with relatively large number of patients that was performed using simultaneous Ce-CT & PET/CT protocol with uniform interpretation criteria.
